{
  "symbol": "REGN",
  "year": 2024,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.2026,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.451
  },
  "top_positive": [
    {
      "sent": "41 Table of Contents Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Dupixent and Kevzara net product sales $ 3,937.3 $ 3,193.3 $ 10,774.3 $ 8,645.7 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,263.4 $ 995.6 $ 3,338.5 $ 2,564.8 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (175.1) (132.6) (457.9) (314.2) Regeneron's share of profits $ 1,088.3 $ 863.0 $ 2,880.6 $ 2,250.6 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 28% 27% 27% 26% The increase in our share of profits for the three and nine months ended September\u00a030, 2024, compared to the same periods in 2023, was driven by higher profits associated with Dupixent sales.",
      "score": 0.9792
    },
    {
      "sent": "41 Table of Contents Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Dupixent and Kevzara net product sales $ 3,937.3 $ 3,193.3 $ 10,774.3 $ 8,645.7 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,263.4 $ 995.6 $ 3,338.5 $ 2,564.8 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (175.1) (132.6) (457.9) (314.2) Regeneron's share of profits $ 1,088.3 $ 863.0 $ 2,880.6 $ 2,250.6 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 28% 27% 27% 26% The increase in our share of profits for the three and nine months ended September\u00a030, 2024, compared to the same periods in 2023, was driven by higher profits associated with Dupixent sales.",
      "score": 0.9792
    },
    {
      "sent": "These provisions include: \u2022 authorization to issue \"blank check\" preferred stock, which is preferred stock that can be created and issued by the board of directors without prior shareholder approval, with rights senior to those of our Common Stock and Class A Stock; \u2022 a staggered board of directors, so that it would take three successive annual shareholder meetings to replace all of our directors; \u2022 a requirement that removal of directors may only be effected for cause and only upon the affirmative vote of at least eighty percent (80%) of the outstanding shares entitled to vote for directors, as well as a requirement that any vacancy on the board of directors may be filled only by the remaining directors; \u2022 a provision whereby any action required or permitted to be taken at any meeting of shareholders may be taken without a meeting, only if, prior to such action, all of our shareholders consent, the effect of which is to require that shareholder action may only be taken at a duly convened meeting; \u2022 a requirement that any shareholder seeking to bring business before an annual meeting of shareholders must provide timely notice of this intention in writing and meet various other requirements; and \u2022 under the New York Business Corporation Law, in addition to certain restrictions which may apply to \"business combinations\" involving our Company and an \"interested shareholder,\" a plan of merger or consolidation of our Company must be approved by two-thirds of the votes of all outstanding shares entitled to vote thereon.",
      "score": 0.977
    }
  ],
  "top_negative": [
    {
      "sent": "Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.",
      "score": -0.9559
    },
    {
      "sent": "We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems.",
      "score": -0.9531
    },
    {
      "sent": "Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions.",
      "score": -0.9371
    }
  ],
  "forward_snippets": [
    "dates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 the costs of developing, producing, and selling products or unanticipated expenses; \u2022 our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "In addition, unless otherwi\nng, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 the costs of developing, producing, and selling products or unanticipated expenses; \u2022 our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "(a) In coll\nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "We believe the information in the table is useful to investors as it demonstrates our pipeline productivity and our ability to innovate, discover, and develop new products, and bring those products to market either alone or based on contractual arrangements with other parties, which has a direct impact on our results of operations and financial condition.",
    "We believe the information in the table is useful to investors as it demonstrates our pipeline productivity and our ability to innovate, discover, and develop new products, and bring those products to market either alone or based on contractual arrangements with other parties, which has a direct impact on our results of operations and financial condition."
  ],
  "curated_text": "Symbol: REGN. Year: 2024. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: 41 Table of Contents Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Dupixent and Kevzara net product sales $ 3,937.3 $ 3,193.3 $ 10,774.3 $ 8,645.7 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,263.4 $ 995.6 $ 3,338.5 $ 2,564.8 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (175.1) (132.6) (457.9) (314.2) Regeneron's share of profits $ 1,088.3 $ 863.0 $ 2,880.6 $ 2,250.6 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 28% 27% 27% 26% The increase in our share of profits for the three and nine months ended September\u00a030, 2024, compared to the same periods in 2023, was driven by higher profits associated with Dupixent sales. 41 Table of Contents Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: Three Months Ended September 30, Nine Months Ended September 30, (In millions) 2024 2023 2024 2023 Dupixent and Kevzara net product sales $ 3,937.3 $ 3,193.3 $ 10,774.3 $ 8,645.7 Regeneron's share of collaboration profits in connection with commercialization of antibodies $ 1,263.4 $ 995.6 $ 3,338.5 $ 2,564.8 Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation (175.1) (132.6) (457.9) (314.2) Regeneron's share of profits $ 1,088.3 $ 863.0 $ 2,880.6 $ 2,250.6 Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales 28% 27% 27% 26% The increase in our share of profits for the three and nine months ended September\u00a030, 2024, compared to the same periods in 2023, was driven by higher profits associated with Dupixent sales. These provisions include: \u2022 authorization to issue \"blank check\" preferred stock, which is preferred stock that can be created and issued by the board of directors without prior shareholder approval, with rights senior to those of our Common Stock and Class A Stock; \u2022 a staggered board of directors, so that it would take three successive annual shareholder meetings to replace all of our directors; \u2022 a requirement that removal of directors may only be effected for cause and only upon the affirmative vote of at least eighty percent (80%) of the outstanding shares entitled to vote for directors, as well as a requirement that any vacancy on the board of directors may be filled only by the remaining directors; \u2022 a provision whereby any action required or permitted to be taken at any meeting of shareholders may be taken without a meeting, only if, prior to such action, all of our shareholders consent, the effect of which is to require that shareholder action may only be taken at a duly convened meeting; \u2022 a requirement that any shareholder seeking to bring business before an annual meeting of shareholders must provide timely notice of this intention in writing and meet various other requirements; and \u2022 under the New York Business Corporation Law, in addition to certain restrictions which may apply to \"business combinations\" involving our Company and an \"interested shareholder,\" a plan of merger or consolidation of our Company must be approved by two-thirds of the votes of all outstanding shares entitled to vote thereon. Top negative sentences: Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims. We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems. Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions. Forward-looking snippets: dates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 the costs of developing, producing, and selling products or unanticipated expenses; \u2022 our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. In addition, unless otherwi\nng, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 the costs of developing, producing, and selling products or unanticipated expenses; \u2022 our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. (a) In coll\nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. We believe the information in the table is useful to investors as it demonstrates our pipeline productivity and our ability to innovate, discover, and develop new products, and bring those products to market either alone or based on contractual arrangements with other parties, which has a direct impact on our results of operations and financial condition. We believe the information in the table is useful to investors as it demonstrates our pipeline productivity and our ability to innovate, discover, and develop new products, and bring those products to market either alone or based on contractual arrangements with other parties, which has a direct impact on our results of operations and financial condition."
}